Objectives
 The model adopts a societal perspective.
 Costs and outcomes were discounted at a 5% annual rate, as recommended by Portuguese guidelines. 5  Clinical efficacy and safety data were based on the published results from the phase 3 idelalisib plus rituximab clinical trial. 6  Survival curves were extrapolated using a Weibull function.
 Utility levels were age adjusted using the results of Kind et al (1999). 7  Disease specific utility values were taken from published evidence (Table 1) . 8  Treatment related adverse events (TRAEs) included are those most commonly observed at grade III/IV in the CLL randomised clinical trials.
Each TRAE was associated to a specific disutility (Table 2) . [8] [9]  The international cost-effectiveness model was adapted to Portuguese health settings and is based on a partitioned survival  The unit costs were taken from Portuguese legislation and NHS references.
 The Diagnosis-Related Groups database (DRG) for 2013 was used to estimate inpatient costs with adverse events (AE). 10 Inpatient episodes were identified using the appropriate code (ICD 9 -CM).
 Univariate and probabilistic sensitivity analyses were performed in order to assess the robustness of results.
 Model outputs included life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs).  Survival gains and direct medical costs were higher with idelalisib in association with rituximab compared to rituximab in monotherapy (Table 3) .
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 Costs related to adverse events and end-of-life care were higher with rituximab in monotherapy (Table 3) . 
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